TÁC DỤNG KHÔNG MONG MUỐN TRÊN DA TRONG ĐIỀU TRỊ THUỐC ỨC CHẾ TYROSINE KINASE BỆNH NHÂN UNG THƯ PHỔI CÓ ĐỘT BIẾN EGFR

Abstract

Objective: Assessing dermatologic adverse events induced by EGFR tyrosine kinase inhibitors for patients with non-small cell lung cancer in the Department of Medical Oncology No1, National Cancer Hospital. Patients and method: 261 patients with metastatic non-small cell lung cancer harboured EGFR and treated with tyrosine kinase inhibitors in the Department of Medical Oncology 1, National Cancer Hospital from 3/2018-04/2022. Method research of description prospective and cross-section. Results: Female was dominated (70.1%) with 65.1% patients less than 65 years old. The most common metastasis was bone metastasis, accounted for 70.1%, then lung metastatis (69.3%). Most of patient had no history of cutanous disease. Major patients was received first generation TKIs with erlotinib and gefitinib, accounted for 39.8% and 45.2%, respectively. Majority of patient had no smoking (72.8%). The majority of patients had AEs rash grade 1 and 2 (36.9% and 44.1%, respectively), one patient presented of grade 4. Paronychia was seen in 63.2% patients, usually grade 1 and 2 (35.8% and 23.6%, respectively), and 6 patients was reported of grade 3. Face-skin was the most common location of cutanous AEs, then chest. Most of patients were outpatient-treated with doctor guides and nursing care, 13 inpatients were reported for medical care at hospital. Conclusion: Dermatologic adverse events induced by EGFR tyrosine kinase inhibitors often Nursing care is extremely important, contributing to improving the quality of life in patients with non-small cell lung cancer treated with TKIs, increasing treatment efficacy and helping the patients to be assured and cooperate in the treatment process.